Sigma Healthcare Ltd (ASX: SIG) Share Price and News
Price
$2.93
Movement
0.04 (-1.35%)
as at 9 Apr - Closed (20 mins delayed)
52 Week Range
$1.075 - $3.32
1 Year Return
+133.47%
Sigma Healthcare Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
$2.93
Day Change
0.04 (-1.35%)
52 Week Range
$1.075 - $3.32
Yesterday's Close
$2.97
Today's Open
$2.93
Days Range
$2.91 - $3.00
Volume
28,528,445
Avg. Volume (1 month)
45,395,197
Turnover
$84,413,970
as at 9 Apr - Closed
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...
See The 5 Stocks *Returns as of 6 March 2025
Sigma Healthcare Ltd (ASX: SIG)
Latest News

Healthcare Shares
Forget Trump! Here are 3 reasons to buy this $32 billion ASX 200 healthcare share today

Broker Notes
6 ASX 200 shares that experts say it's time to sell

Share Gainers
Here are the top 10 ASX 200 shares today

Earnings Results
Sigma shares climb after reporting massive 878% profit jump for FY25

Share Market News
Which ASX 200 sectors were the most resilient during the market sell-off?

Opinions
2 high-quality ASX stocks to buy as the tariff sell-off worsens

Healthcare Shares
This little-known healthcare company is now the 17th-largest business in the ASX 200

Share Gainers
Here are the top 10 ASX 200 shares today

52-Week Highs
These ASX 200 shares just hit new 52-week highs

Share Gainers
Here are the top 10 ASX 200 shares today

Share Gainers
Here are the top 10 ASX 200 shares today

Healthcare Shares
Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
01 Oct 2024 | $0.0050 | 0.00% | Interim | 17 Oct 2024 |
28 Mar 2024 | $0.0050 | 50.00% | Final | 17 Apr 2024 |
25 Sep 2023 | $0.0050 | 100.00% | Interim | 11 Oct 2023 |
30 Mar 2023 | $0.0050 | 100.00% | Final | 18 Apr 2023 |
29 Sep 2022 | $0.0050 | 100.00% | Interim | 12 Oct 2022 |
04 Apr 2022 | $0.0100 | 100.00% | Final | 22 Apr 2022 |
24 Sep 2021 | $0.0100 | 100.00% | Interim | 08 Oct 2021 |
06 Apr 2021 | $0.0100 | 100.00% | Final | 21 Apr 2021 |
19 Sep 2019 | $0.0100 | 100.00% | Interim | 04 Oct 2019 |
03 Apr 2019 | $0.0200 | 100.00% | Final | 29 Apr 2019 |
12 Oct 2018 | $0.0150 | 100.00% | Interim | 29 Oct 2018 |
05 Apr 2018 | $0.0250 | 100.00% | Final | 20 Apr 2018 |
19 Sep 2017 | $0.0250 | 100.00% | Interim | 05 Oct 2017 |
06 Apr 2017 | $0.0300 | 100.00% | Final | 21 Apr 2017 |
20 Sep 2016 | $0.0250 | 100.00% | Interim | 03 Oct 2016 |
06 Apr 2016 | $0.0300 | 100.00% | Final | 21 Apr 2016 |
03 Apr 2014 | $0.0200 | 100.00% | Final | 30 Apr 2014 |
21 Sep 2012 | $0.0200 | 100.00% | Interim | 26 Oct 2012 |
05 Apr 2011 | $0.1500 | 100.00% | Special Cash | 11 May 2011 |
16 Oct 2009 | $0.0300 | 100.00% | Interim | 13 Nov 2009 |
31 Mar 2009 | $0.0400 | 100.00% | Final | 07 May 2009 |
30 Sep 2008 | $0.0300 | 100.00% | Interim | 29 Oct 2008 |
29 Aug 2005 | $0.0200 | 100.00% | Interim | 15 Sep 2005 |
02 Mar 2004 | $0.2000 | 100.00% | Final | 23 Mar 2004 |
SIG ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
25th Mar 2025 2025-03-25T10:39:43 | Sigma AGM Extension | YesNo | 10:39am | 2 | 191k |
21st Mar 2025 2025-03-21T15:43:52 | Additional Clarifying Information - Appendix 4E | YesNo | 3:43pm | 1 | 152k |
20th Mar 2025 2025-03-20T08:45:33 | Sigma Full Year 2024/25 ASX Release | YesNo | 8:45am | 3 | 290k |
20th Mar 2025 2025-03-20T08:44:48 | Sigma Appendix 4E & Full Year Financial Report | YesNo | 8:44am | 94 | 1.7M |
7th Mar 2025 2025-03-07T17:01:18 | S&P DJI Announces March 2025 Quarterly Rebalance | YesNo | 5:01pm | 8 | 179k |
27th Feb 2025 2025-02-27T19:21:03 | Roadshow Presentation including CW 1H25 Results | YesNo | 7:21pm | 24 | 3.7M |
27th Feb 2025 2025-02-27T13:22:51 | Application for quotation of securities - SIG | YesNo | 1:22pm | 6 | 16k |
18th Feb 2025 2025-02-18T18:44:14 | Ceasing to be a substantial holder | YesNo | 6:44pm | 6 | 546k |
18th Feb 2025 2025-02-18T15:00:43 | Application for quotation of securities - SIG | YesNo | 3:00pm | 6 | 16k |
18th Feb 2025 2025-02-18T14:57:33 | Application for quotation of securities - SIG | YesNo | 2:57pm | 6 | 16k |
About Sigma Healthcare Ltd
Sigma Healthcare Ltd. engages in the manufacture and distribution of pharmaceutical products through pharmacy, grocery channels, and private label. The firm operates through the Amcal, Guardian, PharmaSave, Chemist King, and Discount Drug Stores retail brands. It also involves in the provision of services to retail pharmacists in Australia. The company was founded on July 2, 1999 and is headquartered in Rowville, Australia.
SIG Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
08 Apr 2025 | $2.97 | $0.15 | 5.32% | 33,609,833 | $2.82 | $2.98 | $2.81 |
07 Apr 2025 | $2.82 | $-0.07 | -2.42% | 37,486,182 | $2.77 | $2.86 | $2.72 |
04 Apr 2025 | $2.89 | $0.00 | 0.00% | 28,792,966 | $2.85 | $2.95 | $2.85 |
03 Apr 2025 | $2.89 | $0.02 | 0.70% | 21,379,622 | $2.80 | $2.91 | $2.78 |
02 Apr 2025 | $2.87 | $0.02 | 0.70% | 18,811,633 | $2.86 | $2.92 | $2.84 |
01 Apr 2025 | $2.85 | $-0.03 | -1.04% | 22,205,765 | $2.91 | $2.91 | $2.78 |
31 Mar 2025 | $2.88 | $-0.01 | -0.35% | 32,815,222 | $2.89 | $2.93 | $2.87 |
28 Mar 2025 | $2.89 | $-0.02 | -0.69% | 13,697,792 | $2.88 | $2.94 | $2.87 |
27 Mar 2025 | $2.91 | $-0.02 | -0.68% | 26,948,973 | $2.91 | $2.93 | $2.84 |
26 Mar 2025 | $2.93 | $0.07 | 2.45% | 28,762,856 | $2.87 | $2.95 | $2.83 |
25 Mar 2025 | $2.86 | $0.06 | 2.14% | 44,103,714 | $2.80 | $2.88 | $2.76 |
24 Mar 2025 | $2.80 | $-0.07 | -2.44% | 37,806,444 | $2.85 | $2.85 | $2.73 |
21 Mar 2025 | $2.87 | $-0.04 | -1.37% | 461,856,090 | $2.91 | $2.95 | $2.81 |
20 Mar 2025 | $2.91 | $0.00 | 0.00% | 25,110,331 | $2.95 | $2.95 | $2.84 |
19 Mar 2025 | $2.91 | $-0.04 | -1.36% | 24,521,563 | $2.94 | $2.96 | $2.90 |
18 Mar 2025 | $2.95 | $-0.01 | -0.34% | 27,223,930 | $2.98 | $3.00 | $2.94 |
17 Mar 2025 | $2.96 | $0.08 | 2.78% | 22,492,444 | $2.90 | $3.00 | $2.89 |
14 Mar 2025 | $2.88 | $0.08 | 2.86% | 13,458,702 | $2.84 | $2.91 | $2.81 |
13 Mar 2025 | $2.80 | $0.04 | 1.45% | 11,242,628 | $2.76 | $2.82 | $2.75 |
12 Mar 2025 | $2.76 | $-0.04 | -1.43% | 28,287,530 | $2.77 | $2.78 | $2.72 |
11 Mar 2025 | $2.80 | $-0.09 | -3.11% | 23,539,597 | $2.87 | $2.88 | $2.73 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
14 Feb 2025 | Vikesh Ramsunder | Exercise | 1,965,878 | $6,133,539 |
Conversion of securities. 1,010,723 - Rights
|
14 Feb 2025 | Damien Gance | Sell | 40,000,000 | $120,000,000 |
Off-market trade.
|
14 Feb 2025 | Vikesh Ramsunder | Buy | 1,965,878 | $6,133,539 |
Conversion of securities.
|
13 Feb 2025 | Vikesh Ramsunder | Sell | 11,662,028 | $34,053,121 |
On-market trade. Average Price
|
12 Feb 2025 | Vikesh Ramsunder | Exercise | 1,167,106 | $3,221,212 |
Conversion of securities. 4,921,778 - Rights
|
12 Feb 2025 | Vikesh Ramsunder | Expiry | 1,945,177 | $5,368,688 |
As advised by the company. 2,976,601 - Rights
lapse of remaining 1,945,177 EEG Rights |
12 Feb 2025 | Vikesh Ramsunder | Buy | 1,167,106 | $3,221,212 |
Conversion of securities.
|
10 Jul 2024 | Annette Carey | Buy | 3,662 | $4,681 |
Directors' share plan.
|
10 Jul 2024 | Christopher Roberts | Buy | 3,661 | $4,680 |
Directors' share plan.
|
10 Jul 2024 | Neville Mitchell | Buy | 4,340 | $5,548 |
Directors' share plan.
|
10 Jul 2024 | Kathryn (Kate) Spargo | Buy | 4,747 | $6,067 |
Directors' share plan.
|
10 Jul 2024 | Michael Sammells | Buy | 7,866 | $10,054 |
Directors' share plan.
|
09 Jul 2024 | Vikesh Ramsunder | Issued | 1,253,717 | $1,611,026 |
Issue of securities. 6,088,884 - Rights
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Christopher Graham Roberts | Non-Executive Director | Oct 2023 |
Dr Roberts has more than 40 years of experience in the medical device industry, including as the former Chief Executive Officer of Cochlear Limited from 2004 to 2015, Executive Vice President of ResMed Inc (NYSE:RMD) from 1992 to 2003 and as a director of ResMed Inc until November 2017. He is currently a non-executive director of HMC Capital Ltd (ASX:HMC). HMC Capital managed HealthcCo Healthcare and Wellness REIT (ASX:HCW), HMC Capital Partners Fund 1, Clarity Pharmaceuticals Limited (ASX:CU6), Nutromics Pty Ltd, Atmo Biosciences Limited and the Cochlear Foundation Board. He is also a Governor of the Centenary Institute Cancer Medicine and Cell Biology.
|
Mr Neville Mitchell | Non-Executive Director | Feb 2023 |
Mr Mitchell has international healthcare and finance experience. He was Chief Financial Officer and Company Secretary at ASX-listed Cochlear Limited, a world leading medical device developer, manufacturer and seller of hearing devices. Mr Mitchell is currently the Chairman of ASX and NZX-listed Fisher&Paykel Healthcare Corporation (non-executive director from November 2018) and a non-executive director of Sonic Healthcare Limited from September 2017. He is Chair of the Sonic Audit Committee. He was formerly a non-executive director of ASX-listed Sirtex Healthcare, Osprey Medical Inc and Q'Biotics Group Limited. He has also performed roles with several industry and Government committees.
|
Mr Michael Sammells | Non-Executive DirectorInterim Chairman | Feb 2020 |
Mr Sammells is also currently a non-executive director at AMP Limited and a director at GMBHA. He has 35 years of broad experience in finance, corporate services and has held operational roles with expertise in finance, accounting, treasury, investor relations, capital development, mergers and acquisitions and IPOs. Further, Mr Sammells is a former Chief Financial Officer of Healthscope Limited and Medibank Private.
|
Mr Vikesh Ramsunder | Chief Executive OfficerManaging Director | Feb 2022 |
Mr Ramsunder has experience in pharmacy retailing, wholesaling and logistics. He spent 28 years with the Clicks Group in South Africa. This included 18 years as part of the executive team. Before becoming Clicks Group Chief Executive Officer in January 2019, Mr Ramsunder held several roles within Clicks, including Chief Operating Officer from 2015 and Managing Director of the pharmaceutical wholesale business, United Pharmaceutical Distributors from 2010.
|
Ms Annette May Carey | Non-Executive Director | Apr 2023 |
Ms Carey is a current non-executive director of National Intermodal Corporation and a non-executive director of the Kinetic bus group. Prior to joining Sigma, Ms Carey has held director roles within the Linfox group of companies and has been Chair or Deputy Chair of Australia Post joint ventures in the UK and China. She has previously held various senior roles within the Linfox Logistics group, progressing from General Counsel and Company Secretary to Chief Executive Officer. Ms Carey also held the position of Executive General Manager International with Australia Post. Ms Carey is a member of Chief Executive Women.
|
Mr Jack Gance | Non-Executive Director | Feb 2025 |
Mr D Gance is a qualified pharmacist who joined MyChemist in 1998 and is currently the Chief Commercial Officer of Chemist Warehouse. Mr D Gance was the first Chemist Warehouse Franchisee opening the first Chemist Warehouse pharmacy in June 2000.
|
Ms Danielle Di Pilla | Non-Executive Director | Feb 2025 |
Ms Di Pilla is a qualified pharmacist who is currently the Chief People Officer at Chemist Warehouse. Ms Di Pilla established DPP Pharmaceuticals Pty Ltd (DPP) in 2000 and is the founder of brands such as Goat Soap, which has had international success. Ms Di Pilla has been the managing director of DPP since it was incorporated. DPP is a wholly owned subsidiary of Chemist Warehouse. Ms Di Pilla also sits on the Board of Gotcha4Life.
|
Mr Mario Verrocchi | Non-Executive Director | Feb 2025 |
Mr Verrocchi joined Jack and Sam Gance's pharmacy group in 1982. Mr Verrocchi established MyChemist with Jack Gance and Sam Gance in 1997 and subsequently created the Chemist Warehouse chain with Messrs Gance in 2000. He is currently Chief Executive Officer of Chemist Warehouse.
|
Mr Damien Gance | Non-Executive Director | Feb 2025 |
Mr J Gance as a pharmacist in 1967 and opened his first pharmacy store in Reservoir, Victoria, with Sam in 1972. In 1997, Mr J Gance, Sam Gance and Mario Verrocchi, established MyChemist and opened the first MyChemist store. In 2000, Mr J Gance, along with Mr Sam Gance and Mr Verrocchi, established the Chemist Warehouse chain and opened the first Chemist Warehouse store. Mr J Gance also created the brands Le Specs, Le Tan and Colours of Australis.
|
Ms Kara McGowan | General CounselCompany Secretary | Oct 2021 |
-
|
Kara McGowan | General CounselCompany Secretary |
-
|
|
Mr M Conway | Chief Financial Officer |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 871,241,938 | 14.61% |
Citicorp Nominees Pty Limited | 445,477,631 | 7.47% |
J P Morgan Nominees Australia Pty Limited | 359,556,170 | 6.03% |
Dgsr Family Foundation Pty Ltd | 353,829,615 | 5.93% |
Av Family Foundation Pty Ltd | 313,784,873 | 5.26% |
Mjv Family Foundation Pty Ltd | 313,784,873 | 5.26% |
Mr Sunil Narula | 165,893,114 | 2.78% |
Bond Street Custodians Limited | 150,545,209 | 2.52% |
Mat Family Foundation Pty Ltd | 148,144,781 | 2.48% |
HMC Capital Partners Holdings Pty Ltd | 103,399,008 | 1.73% |
Ms Nancy Fei Fei Jian | 86,118,340 | 1.44% |
HSBC Custody Nominees (Australia) Limited Gsco Eca | 75,333,468 | 1.26% |
Mr Azman Rashid Haroon | 64,502,845 | 1.08% |
Ms Danielle Di Pilla | 61,243,218 | 1.03% |
Mr Claudio Avendano | 55,986,398 | 0.94% |
Citicorp Nominees Pty Limited i | 51,603,737 | 0.87% |
Bond Street Custodians Limited i | 48,455,727 | 0.81% |
Di Pilla Investments Pty Ltd | 44,228,054 | 0.74% |
Mr William Ho | 41,669,145 | 0.70% |
Bond Street Custodians Limited ii | 41,505,949 | 0.73% |
Mr Anthony Paul Bassaly | 39,768,975 | 0.67% |